This trial is active, not recruiting.

Conditions chronic myeloproliferative disorders, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic-myeloproliferative diseases, psychosocial effects of cancer and its treatment
Treatment psychosocial assessment and care
Sponsor The Cleveland Clinic
Collaborator National Cancer Institute (NCI)
Start date February 2006
End date December 2008
Trial size 36 participants
Trial identifier NCT00281814, CASE-CCF-1035, CASE-CCF-6950, P30CA043703


RATIONALE: Questionnaires that measure coping may improve the ability to plan supportive care for patients undergoing donor bone marrow transplant.

PURPOSE: This clinical trial is studying coping in patients who are undergoing a donor bone marrow transplant.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Compare modes of illness adjustment, presence or absence of an inpatient lay care-partner, and survival rates
time frame: Through 100 days post transplant

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Medically suitable for allogeneic bone marrow transplantation PATIENT CHARACTERISTICS: - Resides locally in the Cleveland, Ohio area PRIOR CONCURRENT THERAPY: - Not specified

Additional Information

Official title Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support
Description OBJECTIVES: - Investigate the relative importance of having a consistent inpatient lay care-partner for patients undergoing allogeneic bone marrow transplantation, in terms of the effects on modes of adjustment to illness and survival. OUTLINE: Patients undergo a 40-minute recorded oral interview in person to provide personal and social demographic data using a 20-item questionnaire (The Adjustment to Illness Questionnaire-Bone Marrow Transplantation) at baseline (pre-transplant) and at day 100 post-transplant. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in March 2011.
Information provided to ClinicalTrials.gov by The Cleveland Clinic.